Ann: 2019 Letter to Shareholders, page-29

Totally agree. It would be comparable to say a "home pregnancy kit" or "home blood pressure machine". Something that can give a quick result and suggest the next steps for full diagnosis and better care for cure. In other words, the same algo's but a dumbed down version of the ResappDX (no data collection, no diagnostic questioning etc) which may need little to no regulatory approval hence deployable to the world quickly and accurately. That's what scaleable means and what they describe their technology as.
My feel is that Sanofi wants to take it out for a few laps with the public and check the general and psychological acceptance of whether coughing into a smart phone will take hold.
At a clinical level, most people just follow a doctors instructions to get them back to health, that part will be left to Resapp to market initially. If Sanofi get positive feedback from the mass marketed dumbed down version, that's when all the fun begins. It's then easy to upgrade the dumbed down version into the all singing and dancing clinical version if that's the course they wish to take.